Dian Diagnostics Group Co., Ltd.

Dian Diagnostics Group Co., Ltd. is a prominent player in China's medical diagnostics sector, listed on the ChiNext board of the Shenzhen Stock Exchange since 2011. The company specializes in third-party diagnostic services and positions itself as a pioneer in intelligent diagnostic solutions. It aims to meet the comprehensive clinical diagnosis and treatment needs of healthcare institutions at various levels, including hospitals, community health service centers, and disease control centers, by providing integrated "Service + Product + Digital" solutions. The company operates across multiple business lines, including medical diagnostic services, diagnostic technology research and development, and the manufacturing and sales of diagnostic products. Dian Diagnostics has developed a nationwide distribution network and a chain of independent medical laboratories to support its operations. It focuses on enhancing efficiency and reducing costs for healthcare institutions through cooperative models and precision centers. By leveraging advanced technologies and a vast array of testing items, the company aims to strengthen its market position and drive innovation in the medical diagnostics field.

Dian Diagnostics possesses core competencies in the following four areas: (i) Leveraging an integrated "Service + Product + Digital" solution that precisely aligns with the development trends of China's medical market, the company has evolved from a single test outsourcing provider into a one-stop comprehensive service partner covering the entire lifecycle of medical institutions. (ii) Having built an integrated "R&D, Manufacturing, Sales, and Testing" industry chain, the company achieves efficient synergies across upstream core technologies, a midstream nationwide service network, and downstream health management, significantly enhancing its risk resistance capabilities and long-term competitive advantages. (iii) Continuously driving technological innovation across multiple technology platforms such as high-throughput sequencing and mass spectrometry, the company fully implements international quality standards including ISO15189 and CAP, and its laboratory management and technical capabilities have received multiple national-level recognitions. (iv) Leveraging extensive test menu items and massive medical testing data accumulated from serving over 22,000 healthcare institutions, along with its digital platform and AI large model initiatives, the company has built a core barrier in digital intelligence and is steadily upgrading toward becoming a leading provider of intelligent diagnostic solutions.